ADC Therapeutics (ADCT) Expected to Release Quarterly Earnings on Tuesday

ADC Therapeutics (NYSE:ADCT) is anticipated to issue its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to post earnings of ($0.19) per share and revenue of $18.8870 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:30 AM ET.

ADC Therapeutics (NYSE:ADCT) last posted its quarterly earnings results on Monday, May 4th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The business had revenue of $20.85 million during the quarter, compared to analysts’ expectations of $19.99 million. During the same period in the previous year, the business posted ($0.36) earnings per share. On average, analysts expect ADC Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ADC Therapeutics Trading Up 3.3%

Shares of ADC Therapeutics stock traded up $0.04 during trading hours on Tuesday, reaching $1.08. The stock had a trading volume of 405,536 shares, compared to its average volume of 1,276,783. The firm has a 50 day simple moving average of $1.47 and a two-hundred day simple moving average of $3.03. The firm has a market capitalization of $138.00 million, a price-to-earnings ratio of -1.03 and a beta of 1.89. ADC Therapeutics has a 1 year low of $0.78 and a 1 year high of $4.98.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of ADC Therapeutics in a research report on Friday, July 17th. Stephens reaffirmed an “overweight” rating and set a $5.00 price target on shares of ADC Therapeutics in a research report on Thursday, June 4th. Wall Street Zen downgraded shares of ADC Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Cantor Fitzgerald reissued an “overweight” rating on shares of ADC Therapeutics in a research report on Thursday, June 4th. Finally, HC Wainwright downgraded shares of ADC Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, June 8th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, ADC Therapeutics currently has an average rating of “Hold” and a consensus target price of $6.25.

Hedge Funds Weigh In On ADC Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Engineers Gate Manager LP purchased a new position in ADC Therapeutics in the 4th quarter worth approximately $43,000. AQR Capital Management LLC raised its stake in shares of ADC Therapeutics by 42.2% during the fourth quarter. AQR Capital Management LLC now owns 206,576 shares of the company’s stock valued at $729,000 after purchasing an additional 61,324 shares during the period. Cantor Fitzgerald L. P. purchased a new stake in shares of ADC Therapeutics during the fourth quarter valued at approximately $353,000. Jump Financial LLC lifted its position in shares of ADC Therapeutics by 1,299.8% during the fourth quarter. Jump Financial LLC now owns 162,250 shares of the company’s stock worth $573,000 after purchasing an additional 150,659 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of ADC Therapeutics by 25.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 46,750 shares of the company’s stock worth $166,000 after purchasing an additional 9,537 shares in the last quarter. 41.10% of the stock is owned by institutional investors and hedge funds.

About ADC Therapeutics

ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.

At the core of ADC Therapeutics’ portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.